Associations - KRAS G12D

KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	panitumumab Resistant: B - Late Trials panitumumab Resistant : B	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	MRTX1133 Sensitive: C2 – Inclusion Criteria MRTX1133 Sensitive : C2	MRTX1133 Sensitive: C2 – Inclusion Criteria MRTX1133 Sensitive : C2
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	MRTX1133 Sensitive: C2 – Inclusion Criteria MRTX1133 Sensitive : C2	MRTX1133 Sensitive: C2 – Inclusion Criteria MRTX1133 Sensitive : C2
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	RMC-9805 Sensitive: C2 – Inclusion Criteria RMC-9805 Sensitive : C2	RMC-9805 Sensitive: C2 – Inclusion Criteria RMC-9805 Sensitive : C2
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3
KRAS G12D	Ovarian Serous Adenocarcinoma	KRAS G12D	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
KRAS G12D	Biliary Tract Cancer	KRAS G12D	Biliary Tract Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12D	Hepatocellular Cancer	KRAS G12D	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	ASTX029 Sensitive: C3 – Early Trials ASTX029 Sensitive : C3	ASTX029 Sensitive: C3 – Early Trials ASTX029 Sensitive : C3
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	regorafenib Sensitive: C3 – Early Trials regorafenib Sensitive : C3	regorafenib Sensitive: C3 – Early Trials regorafenib Sensitive : C3
KRAS G12D	Pancreatic Ductal Adenocarcinoma	KRAS G12D	Pancreatic Ductal Adenocarcinoma	gemcitabine + paclitaxel Resistant: C3 – Early Trials gemcitabine + paclitaxel Resistant : C3	gemcitabine + paclitaxel Resistant: C3 – Early Trials gemcitabine + paclitaxel Resistant : C3
KRAS G12D	Gallbladder Cancer	KRAS G12D	Gallbladder Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	regorafenib Sensitive: C4 – Case Studies regorafenib Sensitive : C4	regorafenib Sensitive: C4 – Case Studies regorafenib Sensitive : C4
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	MK-2206 Sensitive: C4 – Case Studies MK-2206 Sensitive : C4	MK-2206 Sensitive: C4 – Case Studies MK-2206 Sensitive : C4
KRAS G12D	Ovarian Serous Adenocarcinoma	KRAS G12D	Ovarian Serous Adenocarcinoma	binimetinib + PF-07284892 Sensitive: C4 – Case Studies binimetinib + PF-07284892 Sensitive : C4	binimetinib + PF-07284892 Sensitive: C4 – Case Studies binimetinib + PF-07284892 Sensitive : C4
KRAS G12D	Lung Cancer	KRAS G12D	Lung Cancer	KS-58 Sensitive: D – Preclinical KS-58 Sensitive : D	KS-58 Sensitive: D – Preclinical KS-58 Sensitive : D
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	IPI-504 Sensitive: D – Preclinical IPI-504 Sensitive : D	IPI-504 Sensitive: D – Preclinical IPI-504 Sensitive : D
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	KS-58 Sensitive: D – Preclinical KS-58 Sensitive : D	KS-58 Sensitive: D – Preclinical KS-58 Sensitive : D
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	BCN057 Sensitive: D – Preclinical BCN057 Sensitive : D	BCN057 Sensitive: D – Preclinical BCN057 Sensitive : D
KRAS G12D	Cholangiocarcinoma	KRAS G12D	Cholangiocarcinoma	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D
KRAS G12D	Cholangiocarcinoma	KRAS G12D	Cholangiocarcinoma	bosutinib Sensitive: D – Preclinical bosutinib Sensitive : D	bosutinib Sensitive: D – Preclinical bosutinib Sensitive : D
KRAS G12D	Cholangiocarcinoma	KRAS G12D	Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D
KRAS G12D	Cholangiocarcinoma	KRAS G12D	Cholangiocarcinoma	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D